Biogen (BIIB) Operating Expenses (2009 - 2026)

Biogen (BIIB) has reported Operating Expenses for 18 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 0.93% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $8.3 billion (up 3.11% YoY), while the FY2025 annual figure was $8.3 billion, up 7.26% from the prior year.
• Operating Expenses came in at $2.1 billion for Q1 2026 at Biogen, down from $2.3 billion in the prior quarter.
• The five-year high for Operating Expenses was $2.7 billion in Q3 2023, with the low at $1.1 billion in Q3 2022.
• Average Operating Expenses over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2024.
• Across the five-year window, Operating Expenses slumped 54.28% in 2022 and jumped 134.88% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $1.9 billion in 2022, then grew by 7.96% to $2.1 billion in 2023, then gained by 3.27% to $2.2 billion in 2024, then increased by 7.96% to $2.3 billion in 2025, then decreased by 10.08% to $2.1 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.1 billion, $2.3 billion, and $2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.